A paraneoplastic limbic encephalitis from an anorectal small cell neuroendocrine carcinoma: a case report

Raffaele Longo1*, Marc Wagner2, Benjamin Savenkoff3, Mathilde Chastenet de Castaing1, Guillaume Desiro1, Zead Tubail3, Laurent Hennequin4, Sinan Ben Mahmoud5, Nathalie Marcon6, Philippe Quetin7, Marco Campitiello1 and Francesca Plastino1

Abstract

Background: Paraneoplastic limbic encephalitis (PLE) is a rare autoimmune neurological syndrome observed in cancer patients. PLE is difficult to diagnose and presents a variable response to treatment, depending on the characteristics of the tumor and neuronal autoantibodies.

Case presentation: A 64-year-old, Caucasian, non-smoker man presented with a rapidly developing cognitive impairment, personality change, spatial disorientation, and short-term memory loss associated with anorexia and cervical and inguinal lymph nodes. The 18F-FDG PET scan documented intensely hypermetabolic lymph nodes, which histologically corresponded to a metastasis from a small cell neuroendocrine carcinoma. The brain MRI revealed a high T2-weighted FLAIR signal of the hippocamps, consisted with a PLE. The presence of anti-neuronal Hu antibodies confirmed the diagnosis. The patient underwent plasmapheresis, associated to a systemic chemotherapy resulting in a partial and temporary improvement of the neurological symptoms. Four cycles of intravenous immunoglobulins were also necessary. After six cures of chemotherapy, the lymph node metastases regressed. However, a new anorectal lesion was detected and was histologically confirmed as a primary small cell neuroendocrine carcinoma, which was treated with concomitant chemoradiotherapy. At the end of this treatment, the patient showed a rapid tumor progression leading to his death.

Conclusions: This case highlights the rare entity, PLE, which is difficult to diagnose and manage. In addition, this is the first published case of PLE associated with an anorectal small cell neuroendocrine carcinoma, which appeared after completion of systemic chemotherapy.

Keywords: Limbic encephalitis, Paraneoplastic, Small cell carcinoma

Background

Paraneoplastic limbic encephalitis (PLE) is an uncommon autoimmune neurological syndrome observed in cancer patients selectively affecting the limbic areas, including hippocampus, amygdala, hypothalamus, cingulate gyrus and limbic cortex [1–6]. PLE is clinically characterized by subacute neuropsychiatric symptoms, such as altered mental status, dementia, mood changes, short-term memory deficit, confusion and seizures [3–6]. At the magnetic resonance imaging (MRI), PLE shows a typical increased signal on T2-weighted FLAIR imaging in the medial temporal lobes [3–6]. The diagnosis must be supported by the identification of specific neuronal autoantibodies [6]. The management is complex and based on a multidisciplinary and combined approach of immunotherapy and specific anticancer treatment [7–26]. The prognosis is usually poor and strictly related to the subtype of neuronal autoantibodies, clinical patient’s status and comorbidities, and cancer characteristics and stage [24–26].

We report a case of a patient showing a PLE associated to a rare, metastatic, anorectal small cell neuroendocrine carcinoma. The patient was a 64-year-old, Caucasian, non-smoker man who presented with a rapidly developing cognitive impairment, personality change, spatial disorientation, and short-term memory loss associated with anorexia and cervical and inguinal lymph nodes. The 18F-FDG PET scan documented intensely hypermetabolic lymph nodes, which histologically corresponded to a metastasis from a small cell neuroendocrine carcinoma. The brain MRI revealed a high T2-weighted FLAIR signal of the hippocampi, consistent with a PLE. The presence of anti-neuronal Hu antibodies confirmed the diagnosis. The patient underwent plasmapheresis, associated with systemic chemotherapy resulting in a partial and temporary improvement of the neurological symptoms. Four cycles of intravenous immunoglobulins were also necessary. After six courses of chemotherapy, the lymph node metastases regressed. However, a new anorectal lesion was detected and was histologically confirmed as a primary small cell neuroendocrine carcinoma, which was treated with concomitant chemoradiotherapy. At the end of this treatment, the patient showed a rapid tumor progression leading to his death.

Conclusions: This case highlights the rare entity, PLE, which is difficult to diagnose and manage. In addition, this is the first published case of PLE associated with an anorectal small cell neuroendocrine carcinoma, which appeared after completion of systemic chemotherapy.

Keywords: Limbic encephalitis, Paraneoplastic, Small cell carcinoma

* Correspondence: rlongo@chr-metz-thionville.fr
1 Division of Medical Oncology, “CHR Metz-Thionville”, 1 Allée du Château, 57085 Ars-Laquenexy, France
Full list of author information is available at the end of the article

© The Author(s). 2019, corrected publication 2022 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
neuroendocrine carcinoma. The primary tumor was diagnosed after completion of systemic chemotherapy.

**Case presentation**

A 64-year-old, Caucasian, non-smoker man was admitted to the neurology division for acute cognitive impairment, personality change, spatial disorientation, and short-term memory loss associated with anorexia. He had no relevant comorbidities. The patient’s history was uneventful. At the clinical examination, we found hard, irregular, cervical and inguinal lymph nodes of 1.5 × 1.5 cm of diameter. Biological tests were all in the normal ranges but chromogranin-A and neuron-specific enolase (NSE) were elevated at 175 ng/ml (NV < 102 ng/ml) and 28 ng/ml (NV < 17 ng/ml). The brain MRI revealed T2-weighted fluid-attenuated inversion recovery (FLAIR) signals of the para hippocampic gyrus and the hippocamps (Fig. 1a-b, red arrows). The electroencephalogram (EEG) showed a 1-min, left, fronto-temporal focal crisis. The 18F-FDG (18F-fluorodeoxyglucose) PET scan documented many cervical and inguinal hypermetabolic lymph nodes (Fig. 1c-d, red arrows), a hypermetabolism of the posterior surface of the right prostate lobe and the right hippocampus (Fig. 1e, red arrow), and a right prefrontal, parietal, and occipital cortical hypometabolism (Fig. 1e, white arrows).

The patient referred to a percutaneous ultrasound-guided core biopsy of both, cervical and inguinal, lymphadenopathies and the prostate gland. Histology revealed a massive infiltration of small, poorly differentiated, tumor cells with scant cytoplasm and prominent mitotic figures (Fig. 1f). At the immunohistochemistry, tumor cells were positive for CD56 (Fig. 1g) and synaptophysin, and negative for cytokeratin AE1/AE3, CK-7, CK-20, chromogranin-A, p53, PAX8, GATA-3, and TTF-1 according to the diagnosis of a lymph

![Fig. 1](image-url)
node metastasis of a poorly differentiated, small cell neuroendocrine tumor. The proliferation index (Ki-67) was elevated at 90%. Prostate histology was consistent with a prostatitis. The lumbar punction did not reveal a pleocytosis (1 white cell/mm³; NV < 1 cells/mm³) but elevated protein levels (1.15 g/L; NV < 0.40 g/L) without any evidence of tumor cells. We documented the presence in the serum and in the cerebrospinal fluid (CSF) of anti-neuronal Hu antibodies in the absence of other neuronal autoantibodies, including anti-Yo, anti-Ri, anti-CV2, anti-Ma2, anti-SOX1, anti-GAD65, anti-Tr, anti-Zic4, anti-Titin, anti-amphiphysin, anti leucine-rich glioma inactivated (LG11), and anti contactin associated protein 2 (CASPR2). The molecular analysis of Cytomegalovirus and Human Herpesvirus-6 (HHV-6) genome in the cerebrospinal fluid (CSF) was negative. This biological pattern confirmed the diagnosis of PLE.

The patient underwent several cycles of plasmapheresis combined with high-dose corticosteroids that partially and temporarily improved neurological symptoms. We started also a systemic chemotherapy by a cisplatin/etoposide regimen. After three cycles of chemotherapy, lymph node metastases partially regressed. The brain MRI revealed a radiological improvement of the limbic lesions (Fig. 2a-b, red arrows) but patient’s neurological symptoms quickly worsened and the patient presented with many episodes of partial epileptic seizures and confusion. In this context, we administered four cycles of intravenous immunoglobulins (IVIgs) in addition to the systemic chemotherapy leading to a rapid and progressive improvement of the neurological symptoms.

After six cycles of systemic chemotherapy, the whole body CT and ¹⁸F-FDG PET scan showed a regression of metastatic lymphadenopathies (Fig. 2c-d, red arrows), an improvement of brain abnormalities (Fig. 2e, red and white arrows) but the presence of a new, anorectal, hypermetabolic tumor lesion (Fig. 3a-b, red arrows). The colonoscopy (Fig. 3c, black arrow) and pelvic MRI (Fig. 3d-e,

![Image](https://example.com/image.png)

Fig. 2 Tumor response to chemotherapy and radiological improvement of the PLE. a-b Reduction of the T2-weighted FLAIR signal of the para hippocampic gyrus and the hippocamps after 3 cycles of chemotherapy (brain MRI: coronal and axial section; red arrows). c-d Partial regression of the left, hypermetabolic peri-aortic adenopathy and complete response of the left, hypermetabolic supraclavicular lymph node after 6 cycles of chemotherapy (PET-scan; red arrows). e Residual, left hypermetabolism of the hippocampus (brain PET-scan; red arrow) and right prefrontal, parietal and occipital cortical hypometabolism (brain PET-scan; white arrows) after 6 cycles of chemotherapy.
red arrows) documented a voluminous tumor of the right rectal wall of 62 × 84 × 162 mm of diameter, infiltrating the prostate, the right seminal vesicle, the internal anal sphincter, the levator ani and the puborectalis muscle. The percutaneous biopsy revealed a small cell neuroendocrine carcinoma.

In order to obtain a better control of this new tumor lesion, we started a concomitant chemoradiotherapy with a carboplatin/etoposide regimen. After completion of treatment, the patient developed a diplopia, which was related to a left intraorbital metastasis. The 18F-FDG PET scan showed also lung, hepatic, lymph node, and peritoneal multiple metastases. In this context, we administered a palliative systemic chemotherapy by weekly topotecan but the patient’s clinical conditions quickly worsened leading to his death.

**Discussion and conclusion**

PLE is a rare, autoimmune neurological syndrome affecting the limbic areas [1–11]. It is usually associated with small cell lung cancer, breast cancer, thymoma, ovarian teratoma and Hodgkin lymphoma [1–11].

PLE is clinically characterized by subacute confusion, altered mental status, mood changes, short-term memory deficit, dementia and seizures [1–5]. The subacute development of short-term memory loss (< 3 months) is usually considered the hallmark of PLE, but other neurological symptoms, such as cerebellar ataxia, progressive encephalomyelopathy, and peripheral neuropathy may be more clinically relevant [3, 4].

CSF analysis shows a mild-to-moderate lymphocytic pleocytosis (usually < 100 white blood cells/mm³) in 60–80% of patients and an elevated IgG index or oligoclonal bands in approximately 50% of cases [3–6].

Brain MRI often reveals an increased signal on T2-weighted FLAIR imaging in the medial temporal lobes, the unilateral or the absence of the temporal involvement being very uncommon [3–6]. In this latter case, the diagnosis should be confirmed by the identification...
of specific anti-neuronal antibodies as several non-immune, neurological disorders could present a similar unilateral radiological picture, including seizures, HHV-6 encephalitis or gliomas [3–6]. HHV-6 encephalitis can precisely mimic PLE but it often shows a particular radiological pattern, including a less confined involvement of the limbic system, haemorrhagic aspects, restricted diffusion abnormalities and contrast uptake, and prominent signs of oedema and mass effect involving one or both inferior-medial temporal lobes, inferior frontal lobes and cingulate gyrus. In addition, the clinical setting is different [3–6].

Several published studies have clearly confirmed the pathogenic role of few anti-neuronal antibodies in PLE. Classical PLE with temporal lobe seizures is associated with onconeural autoantibodies directed against intracellular antigens, including anti-Hu, anti-Ma2, anti-amphiphysin, and anti-collapsin response mediator protein 5 (CRMP5). Recently, many autoantibodies to neuronal extracellular epitopes have been described, such as the voltage-gated potassium channel (VGKC) complex, N-methyl-D-aspartate receptor (NMDAR), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR), γ-aminobutyric acid B receptor (GABA_B), LGI1, and CASPR2 [3–6, 12].

Histologically, PLE shows particular inflammatory features, including perivascular lymphocytic cuffs, neuronal loss, reactive microglial nodules and gliosis of the temporal lobe [3].

The diagnosis remains a challenge and generally requires a combination of clinical, biological, and radiological findings [3–6]. Additionally, metabolic and inflammatory encephalopathy, neurotoxic drugs, brain tumors and neurodegenerative disorders must be excluded [3–6]. The brain MRI is more useful to rule out other disorders [3]. The 18F-FDG PET scan might be necessary, particularly when MRI is not conclusive [13–22].

The identification of specific circulating autoantibodies is essential for a definitive diagnosis [3–6]. The onconeural antibodies targeting intracellular proteins of the neuroectodermal tissues are usually characterized by a permanent lymphocyte-T mediated neuronal loss with a low response to the immunomodulatory treatment. On the contrary, the prognosis of PLE associated to the autoantibodies targeting the cell surface antigens is usually better as the neuronal dysfunction is often reversible after the immunosuppressive treatment [3–6].

The management of PLE is complex and based on a multidisciplinary combined approach, including immunotherapy and specific anticancer treatment [23–26]. Different immunomodulator treatments, such as corticosteroids, plasma exchange, immune adsorption or IVIgs, have been reported in the literature with variable results [23–26]. The anticancer treatment plays a pivotal role and should always be used in combination with immunotherapy as this combined approach clearly appears more effective [23–26]. A relatively small percentage of PLE patients experienced symptom stabilization or neurological improvement after immunomodulatory therapy, although most failed to achieve a response until the primary tumor was controlled [24, 25].

In our case, the patient presented with a PLE associated to a rare anorectal small cell neuroendocrine carcinoma that was diagnosed after completion of systemic chemotherapy. Considering the lack of response to plasmapheresis and high-dose corticosteroids, four cycles of IVIgs were administered in addition to chemotherapy leading to a quickly clinical improvement of neurological symptoms. We performed also a concomitant chemoradiotherapy for a better control of the anorectal tumor but the patient showed a rapid, multi-visceral, tumor progression leading to his death.

This case highlights the rare entity, PLE, which is difficult to diagnose and manage. At our knowledge, it is the first published case of a PLE associated to an anorectal small cell neuroendocrine carcinoma. The diagnosis of the primary tumor was a challenge as the patient presented only with metastatic lymph nodes at his first clinical examination. The 18F-FDG PET scan showed an abnormal hypermetabolism of the posterior surface of the right prostate lobe. The clinical examination and the prostate biopsy did not document any pathological lesion but this does not exclude a microscopic tumor of the anorectal mucosa. It is impossible to histologically discriminate a primary anorectal tumor from a metastasis. However, despite the excellent response of lymph node metastases after completion of chemotherapy, a new, voluminous anorectal tumor was diagnosed at the same site where the first 18F-FDG PET scan found the abnormal hypermetabolism. All these considerations and the clinical behavior of this new lesion, which progressed during chemotherapy in contrast to lymph node metastases, support the hypothesis of a primary anorectal tumor, which was resistant to chemotherapy.

**Abbreviations**
- 18F-FDG: 18F-fluorodeoxyglucose; AMPAR: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; CRMP5: Collapsin response mediator protein 5; CSF: Cerebrospinal fluid; EEG: Electroencephalogram; FLAIR: Fluid-attenuated inversion recovery; GABA_B: γ-aminobutyric acid B receptor; HHV-6: Human Herpesvirus-6; IVIgs: Intravenous immunoglobulins; LE: Limbic encephalitis; MRI: Magnetic resonance imaging; NMDAR: N-methyl-D-aspartate receptor; NSE: Neuron-specific enolase; PLE: Paraneoplastic limbic encephalitis; VGKC: Voltage-gated potassium channel

**Acknowledgements**
Dr. Gehin William for the English revision.

**Authors’ contributions**
The patient was admitted under the care of RL and underwent systemic chemotherapy by RL, MCC, GD, MC, and FP. Neuroradiology imaging was performed by LH and SBM. Diagnosis of PLE was made by MW.
Plasmapheresis was performed by BS and ZT. The IVIgs were administered by MW. Histology pictures were made by NM. Radiotherapy was performed by PQ, RL, MW, BS, MCC, GD, ZT, LH, SBR, NM, PQ, MC, and FP substantially contributed to conception, acquisition, analysis and interpretation of data. All authors have been involved in drafting, revising and approving the final manuscript.

Funding
Not applicable.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request. All data and materials are available for review at the Division of Medical Oncology, CHR Metz-Thionville, in an electronic format.

Ethics approval and consent to participate
A written informed consent was obtained from the patient for publication of this Case report and any accompanying images. It is available for review by the Editor-in-Chief of the journal.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Division of Medical Oncology, “CHR Metz-Thionville”, 1 Allée du Château, 57085 Ars-Laquenexy, France. 2 Division of Neurology, “CHR Metz-Thionville”, 1 Allée du Château, 57085 Ars-Laquenexy, France. 3 Division of Nephrology, “CHR Metz-Thionville”, 1 Allée du Château, 57085 Ars-Laquenexy, France. 4 Division of Radiology, “CHR Metz-Thionville”, 1 Allée du Château, 57085 Ars-Laquenexy, France. 5 Division of Pathology, “CHR Metz-Thionville”, 1 Allée du Château, 57085 Ars-Laquenexy, France. 6 Division of Radiotherapy, “CHR Metz-Thionville”, 1 Allée du Château, 57085 Ars-Laquenexy, France.

Received: 15 February 2019 Accepted: 25 November 2019
Published online: 29 November 2019

References
1. Corsellis JA, Goldberg GJ, Norton AR. “Limbic encephalitis” and its association with carcinoma. Brain. 1968;91(3):481–96.
2. Homnorn J, Antoine J-C. Paraneoplastic neurological syndromes. Orphanet J Rare Dis. 2007;2:222.
3. Graus F, Titulaer MJ, Balu R, Benderly S, Bien CG, Cellucci T, et al. Clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15(4):391–404.
4. Graus F, Dalmau J. CNS autoimmunity: new findings and pending issues. Lancet Neurol. 2012;11(1):17–9.
5. Gravitt R, Cavalcante WC, Castro LHM, Nitrini R, Simbakuku MM. Updates in the diagnosis and treatment of paraneoplastic neurologic syndromes. Curr Oncol Rep. 2018;20(11):92.
6. Höftberger R, Rosenfeld MR, Dalmau J. Update on neurological paraneoplastic syndromes. Curr Opin Oncol. 2015;27(6):489–95.
7. Shen K, Xu Y, Guan H, Zhong W, Chen M, Zhao J, et al. Paraneoplastic limbic encephalitis associated with lung cancer. Sci Rep. 2018;8(1):6792.
8. Shin KJ, Ji Y. Anti-Hu antibody-mediated limbic encephalitis associated with cervical cancer: a case report. J Obstet Gynaecol Res. 2018;44(6):1811–4.
9. Inoue T, Kanno R, Motiya A, Nakamura K, Watanabe Y, Matsumura Y, et al. A case of paraneoplastic limbic encephalitis in a patient with invasive thymoma with anti-glutamate receptor antibody-positive cerebrospinal fluid: a case report. Ann Thorac Cardiovasc Surg. 2018;24(2):200–4.
10. Kobayashi M, Nishioka K, Takahashi M, Hatton A, Shoijima Y, Hayashi H, et al. Anti-NM-MAb receptor encephalitis due to large-cell neuroendocrine carcinoma of the uterus. J Neurol Sci. 2017;383:72–7.
11. Pastuszak Z, Stepien A, Tomczykiewicz K, Pliusińska-Macoch R, Kordowska J, Galbarczyk D, et al. Limbic encephalitis - a report of four cases. Cent Eur J Immunol. 2017;42(2):213–7.
12. Ramanathan S, Mohammad SS, Brijot F, Dale RC. Autoimmune encephalitis: recent updates and emerging challenges. J Clin Neurosci. 2014;21(5):722–30.
13. Schmidt SL, Schmidt JJ, Tolentino JC, Ferreira CG, Almeida SA, Alvarenga RP, et al. Cholangiocarcinoma associated with limbic encephalitis and early cerebral abnormalities detected by 2-deoxy-2-[fluorine-18]fluoro-D-glucose integrated with computed tomography-position emission tomography: a case report. J Med Case Reports. 2016;10:200.
14. Goftin KE, Ooms D, Ahmad R, Dermaer S, Van Paeschen W, Van Laere K, et al. Metabolic-structural concordance in paraneoplastic limbic encephalitis. Eur J Nucl Med Mol Imaging. 2016;43(5):994–5.
15. Cózar Santiago MDel P, Sanchez Jurado R, Sanz Llorens R, Aguilar Santos JE, Ferrer Rebollada J. Limbic Encephalitis diagnosed with 18F-FDG PET/CT. Clin Nucl Med. 2016;41(2):101–3.
16. Da Rocha AJ, Nunes RH, Maia AC, Jr, do Amaral LL. Recognizing autoimmune-mediated encephalitis in the differential diagnosis of limbic disorders. AJNR Am J Neuroradiol. 2015;36(12):2196–205.
17. Quartuccio N, Caobelli F, Evangelista L, Aloni P, Kirienko M, De Biasi V, et al. The role of PET/CT in the evaluation of patients affected by limbic encephalitis: A systematic review of the literature. J Neuroimmunol. 2015;284:44–8.
18. Masangkay N, Basu S, Moghbel M, Kwee T, Alavi A. Brain 18F-FDG-PET characteristics in patients with paraneoplastic neurological syndrome and its correlation with clinical and MRI findings. Nucl Med Commun. 2014;35(10):1038–46.
19. Baumgartner A, Rauer S, Mader J, Meyer PT. Cerebral FDG-PET and MRI findings in autoimmune limbic encephalitis: correlation with autoantibody types. J Neurol. 2013;260(11):2744–53.
20. Serrano Vicente J, García Bernardo L, Durán Barquero C, Infante Torre JR, Rayo Madrid J, Domínguez Grande ML. Brain metabolic changes in limbic encephalitis evidenced by 18F-FDG PET. Correlation with symptomatology. Rev Esp Med Nucl Imagen Mol. 2013;32(3):201–2.
21. Fisher BE, Patel NR, Lai EC, Schulz PE. Two different 18F-FDG brain PET metabolic patterns in autoimmune limbic encephalitis. Clin Nucl Med. 2012;37(9):e213–8.
22. Kim TJ, Lee ST, Shin JW, Moon J, Lim JA, Byun JI, et al. Clinical manifestations and outcomes of the treatment of patients with GABAB encephalitis. J Neuroimmunol. 2014;270(1–2):245–50.
23. Gatsalidou M, Thouin A, Vincent A. Antibody-mediated autoimmune encephalopathies and immunotherapies. Neurotherapeutics. 2016;13(1):147–62.
24. Grisold W, Giometto B, Vitaliani R, Oberndorfer S. Current approaches to the role of PET/CT in the evaluation of patients affected by limbic encephalitis. Rev Bras Cardiol. 2018;105(2):92–4.
25. Pelosof LC, Gerber DE. Paraneoplastic syndromes: an approach to diagnosis and treatment. Mayo Clin Proc. 2010;85(9):838–49.
26. Giometto B, Vitaliani R, Nobili F, Oberndorfer S. Use of intravenous immunoglobulin for the treatment of autoimmune encephalitis: audit of the NHS experience. JRSM Open. 2018;9(9):1–5.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication online
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress. Learn more on biomedicalcentral.com/submissions